Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Polifarma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dong-A ST Signs License-out Deal with Polifarma of T\u00fcrkiye for NESP\u00ae Biosimilar DA-3880","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Darbepoetin alfa

    Menu

    Darbepoetin alfa

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dong-A ST Co., Ltd.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880

              Details:

              According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.

              Lead Product(s): Darbepoetin alfa

              Therapeutic Area: Hematology Product Name: DA-3880

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Polifarma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY